

Effect of Duration of Disease on Ventilatory Function in an Ethnic Saudi Group of Diabetic Patients

Sultan A. Meo, MBBS, Ph.D.,¹ Abdul Majeed Al Drees, Ph.D.,¹ Jehangeer Ahmed, MBBS, MRCP,² Sayed Fayaz Ahmed Shah, MBBS, MRCP,² Khalid Al-Regaiey, Ph.D.,¹ Ashraf Husain, M.D., MRCPI,¹ and Khalid Al-Rubean, MBBS, FRCP³

Abstract

Background:

Diabetes mellitus is a leading cause of illness and death across the world and is responsible for a growing proportion of global health care expenditures. The present study was designed to observe the effect of diabetes mellitus on lung function in patients with diabetes belonging to a specific ethnic group, namely Saudis.

Method:

In this study, a group of 47 apparently healthy volunteer male Saudi patients with diabetes was randomly selected. Their ages ranged from 20 to 70 years. The patients were matched with another group of 50 healthy male control subjects in terms of age, height, weight, ethnicity, and socioeconomic status. Both groups met exclusion criteria as per standard. Spirometry was performed with an electronic spirometer (Schiller AT-2 Plus, Switzerland), and results were compared by a Student's *t* test.

Results:

Subjects with diabetes showed a significant reduction in forced vital capacity (FVC) and forced expiratory volume in the first second (FEV₁) relative to their matched controls. However, there were no significant differences in the forced expiratory ratio (FEV₁/FVC%) and the middle half of the FVC (FEF_{25-75%}) between the groups. We observed a significantly negative correlation between duration of disease and pulmonary function, as measured by FEV₁ ($r = 0.258$, $p = 0.04$), FVC ($r = 0.282$, $p = 0.28$), and the middle half of the FVC (FEF_{25-75%}) ($r = 0.321$, $p = 0.014$).

Conclusions:

Pulmonary function in a specific ethnic group of patients with diabetes was impaired as evidenced by a decrease in FVC and FEV₁ compared to pulmonary function in matched controls. Stratification of results by years of disease revealed a significant correlation between duration of disease and a decline in pulmonary function.

J Diabetes Sci Technol 2007;1(5):page numbers

Author Affiliations: ¹Department of Physiology, College of Medicine, King Khalid University Hospital, Riyadh, Saudi Arabia; ²Department of Medicine, College of Medicine, King Khalid University Hospital, Riyadh, Saudi Arabia; and ³Diabetic Centre, King Abdul Aziz University Hospital, King Saud University Riyadh, Riyadh, Saudi Arabia

Abbreviations: (FEF_{25-75%}) force expiratory flow, (FEV₁) force expiratory volume in 1 second, (FEV₁/FVC) force expiratory ratio, (FVC) force vital capacity

Keywords: diabetes mellitus, lung function test, spirometry

Corresponding Author: Sultan Ayoub Meo, MBBS, Ph.D., Department of Physiology (29), College of Medicine, King Khalid University Hospital, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia; email address sultanmeo@hotmail.com or smeo@edu.ksu.sa

Introduction

Diabetes mellitus is a leading public health care problem with increasing incidence and long-term complications. In 2003, 194 million people had diabetes mellitus; by 2025 approximately 333 million will develop diabetes mellitus, and almost 1 million people die each year because of diabetes mellitus.¹ Diabetes mellitus is associated with an ongoing malfunction of numerous organs,² and its complications are mainly a consequence of macrovascular and microvascular damage.³ The mechanism by which impaired glycemic control may lead to a reduction in lung function is uncertain, although it has been suggested that the increased systemic inflammation associated with diabetes⁴ may result in pulmonary inflammation⁵ and hence airway damage.⁶ Moreover, hyperglycemia can cause a secondary reduction in antioxidant defense of the lungs and increased susceptibility to environmental oxidative insults, which can result in a subsequent loss of respiratory function.⁷

Immense interest has been focused on the complications of diabetes, including coronary artery disease, diabetic nephropathy, retinopathy, and neuropathy; however, the pulmonary complications of diabetes mellitus have been poorly characterized. Some authors have reported normal pulmonary function,⁸ whereas others found abnormal lung function.^{9,10} Few studies have been conducted that considered the association between duration of disease and pulmonary function stratified according to such demographic variables as age, height, weight, smoking, ethnic background, and socioeconomic status. Moreover, physicians should be aware of the pulmonary complications in diabetes when they prescribe novel insulin delivery systems, such as inhaled insulin. Therefore, the present study was designed to determine the effect of the disease on respiratory function in patients with diabetes who belong to a specific ethnic group, namely Saudis.

Subjects and Methods

This study was conducted at the Department of Physiology, College of Medicine and Diabetic Center, King Abdul Aziz University Hospital, King Saud University, Riyadh, Saudi Arabia. In this study we obtained institutional approval in compliance with regulation of our institution and with generally accepted guidelines governing such work.

Subjects

The principal investigator and coinvestigators reviewed 348 medical files of patients with diabetes. Patients were then invited to the diabetic center and interviewed. A detailed clinical history was taken with regard to smoking cigarettes and other tobacco products. After the initial interviews, 47 apparently healthy male patients with diabetes with a mean age of 46.45 ± 2.21 years (mean \pm SEM), age range of 20–75 years, and mean duration of disease of 10.60 ± 1.11 years were selected. Their duration of disease ranged from 1 to 30 years. An additional 301 patients were excluded. Of these 47 patients with diabetes, 23 had type 1 and 24 had type 2. Controls were selected in a similar manner to that of the patients with diabetes. We interviewed 180 healthy people and selected 50 apparently healthy male control subjects with a mean age of 45.58 ± 1.74 years and an age range of 29–71 years. Patients with diabetes were individually matched with controls for age, height, and weight. Matching between both groups was within ± 3 years for age, ± 4 centimeters for height, and ± 5 kilograms for weight. Overall, there were no significant differences in anthropometric means in combined or stratified data. Ethnicity, age, and height were given more emphasis for matching, as these three relate better to lung function than weight.¹¹ Controls were from a similar community with the same socioeconomic status relative to patients with diabetes. All subjects had never smoked. All subjects completed a questionnaire, which included anthropometric data and a consent form. The ethics committee at the College of Medicine approved the study. The present study is a continuation of previous studies^{9,10}; however, this work has been updated. New subjects and case controls have been matched and added according to central criteria specified (ethnicity, age, height, weight, smoking, socioeconomic status, etc.).

Exclusion Criteria

Subjects with gross abnormalities of the vertebral column or thoracic cage, known history of acute or chronic respiratory infections, neuromuscular disease, malignancy, cardiopulmonary disease, or a history of major abdominal or chest surgery were excluded from the study. In addition, subjects with current or previous drug or tobacco (smoked or chewed) addictions were excluded. Patients with complications of diabetes such as neuropathy, nephropathy, and retinopathy were also excluded from the study.

Spirometry

Spirometry was performed with an electronic spirometer (Schiller). All pulmonary function tests were carried out at a fixed time of the day (10.00–14.00 hours) to minimize diurnal variation.¹² The apparatus was calibrated daily and operated within the ambient temperature range of 20–25° C. The precise technique in executing various lung function tests for the present study was based on the operating manual of the instrument with reference to the official statement of the American Thoracic Society of Standardization of Spirometry (1987).¹³ After the study, subjects provided a detailed history and anthropometric data, were trained about the entire maneuver, and were encouraged to practice this maneuver before doing the pulmonary function tests. The tests were performed (with each subject in the standing position) by using a nose clip. The tests were repeated three times after adequate rest. The parameters that were measured included force vital capacity (FVC), force expiratory volume in 1 second (FEV₁), force expiratory ratio (FEV₁/FVC), and force expiratory flow (FEF_{25–75%}).

Statistical Analysis

Statistical analysis was conducted using a Student's *t* test for independent groups (two tailed), initially on all matched pairs of subjects and then in three subsets of our study subjects, which were divided according to their duration of disease (less than 5 years, 5–12 years, and

more than 12 years). The level of significance was taken as $p < 0.05$. Pulmonary function data were correlated against the duration of exposure. Linear regression was applied on this correlation, and the equation $y = mx + c$ was derived with the correlation coefficient (*r*). The level of significance of correlation was determined by the *r* value.

Results

Results are presented as both overall and stratified according to the duration of disease in patients with diabetes (less than 5 years, 5–12 years, and more than 12 years). In **Tables 1–4**, the formal statistical comparison of the “matching” variables (age, height, and weight) was thought to be appropriate, as these variables were observed to be similar for the two groups and hence statistical confirmation of this fact is not discussed.

Overall Group Results

Lung function data for diabetic patients and their matched controls are shown in **Table 1**. Patients with diabetes had statistically significant reductions in FVC and FEV₁. The means for FEV₁/FVC%, FEF_{25–75%}, and FEF_{75–85%} were not significantly different between the two groups. The mean duration of disease for patients with diabetes was 10.60 ± 1.11 years (mean ± SEM), with a range of 1 to 30 years.

Table 1.
Anthropometric and Lung Function Data for Total Diabetic Patients Compared with Their Matched Controls

Parameter	Diabetic patients (mean ± SEM) (n = 47)	Control subjects (mean ± SEM) (n = 50)	Percentage change (%)	<i>p</i> value
Age (years)	46.45 ± 2.21	45.58 ± 1.74	-1.90	NS ^a
Height (cm)	168.27 ± 1.13	169.30 ± 1.08	+0.60	NS
Weight (kg)	79.48 ± 1.79	84.30 ± 1.76	+5.71	NS
FVC (liters)	3.33 ± 0.13	3.74 ± 0.66	+10.96	0.012
FEV ₁ (liters)	2.79 ± 0.12	3.13 ± 0.07	+10.86	0.016
FEV ₁ /FVC%	84.13 ± 1.55	84.25 ± 0.83	+0.14	NS
FEF _{25–75%} (liters/s)	3.34 ± 0.21	3.76 ± 0.16	+11.17	NS
FEF _{75–85%} (liters/s)	1.30 ± 0.11	1.50 ± 0.13	+13.33	NS

^aNonsignificant.

Table 2.
Anthropometric and Lung Function Data for Diabetic Patients with Duration of Disease Less Than 5 Years Compared with Their Matched Controls

Parameter	Diabetic patients (mean ± SEM) (n = 17)	Control subjects (mean ± SEM) (n = 50)	Percentage change (%)	<i>p</i> value
Age (years)	38.65 ± 3.56	45.58 ± 1.74	+15.20	NS ^a
Height (cm)	170.00 ± 2.47	169.30 ± 1.08	-0.41	NS
Weight (kg)	78.82 ± 3.54	84.30 ± 1.76	+6.50	NS
FVC (liters)	3.68 ± 0.20	3.74 ± 0.66	+1.60	NS
FEV ₁ (liters)	3.12 ± 0.18	3.13 ± 0.07	+0.31	NS
FEV ₁ /FVC%	85.14 ± 1.82	84.25 ± 0.83	-1.05	NS
FEF _{25–75%} (liters/s)	3.80 ± 0.41	3.76 ± 0.16	-1.06	NS
FEF _{75–85%} (liters/s)	1.44 ± 0.22	1.50 ± 0.13	+4.00	NS

^aNonsignificant.

Table 3.
Anthropometric and Lung Function Data for Diabetic Patients with Duration of Disease 5–12 Years Compared with Their Matched Controls

Parameter	Diabetic patients (mean ± SEM) (n = 11)	Control subjects (mean ± SEM) (n = 50)	Percentage change (%)	p value
Age (years)	49.73 ± 4.19	45.58 ± 1.74	-9.10	NS ^a
Height (cm)	166.18 ± 2.28	169.30 ± 1.08	+1.84	NS
Weight (kg)	79.54 ± 2.95	84.30 ± 1.76	+5.64	NS
FVC (liters)	3.16 ± 0.29	3.74 ± 0.66	+15.50	0.021
FEV ₁ (liters)	2.74 ± 0.26	3.13 ± 0.07	+12.46	NS
FEV ₁ /FVC%	86.69 ± 3.04	84.25 ± 0.83	-2.89	NS
FEF _{25–75%} (liters/s)	3.68 ± 0.41	3.76 ± 0.16	+2.12	NS
FEF _{75–85%} (liters/s)	1.25 ± 0.23	1.50 ± 0.13	+16.66	NS

^aNonsignificant.

Duration of Disease Less Than 5 Years

Table 2 summarizes the comparison of lung function parameters between patients with diabetes and their matched control group. There was no significant difference between the means of any lung function data between the groups. The mean duration of disease for patients with diabetes was 2.82 ± 0.23 years (mean ± SEM), with a range of 1 to 4 years.

Duration of Disease 5–12 Years

There were no significant differences among the means of FEV₁, FEV₁/FVC%, FEF_{25–75%}, and FEF_{75–85%} for patients with diabetes on the basis of duration of disease 5–12 years compared with their matched controls (Table 3). However, patients with diabetes did show a significant reduction in FVC. The mean duration of disease in patients with diabetes was 8.45 ± 0.82 years (mean ± SEM), with a range of 5 to 12 years.

Duration of Disease More Than 12 Years

Patients with diabetes with duration of disease more than 12 years showed a significant reduction in FVC, FEV₁, and FEF_{25–75%} relative to their matched controls (Table 4). Similarly, the percentage change in diabetic patient's data relative to controls was also decreased for FVC, FEV₁, and FEF_{25–75%}. However, there was no significant difference in FEV₁/FVC% and FEF_{75–85%} data relative to controls. The

Table 4.
Anthropometric and Lung Function Data for Diabetic Patients with Duration of Disease Greater Than 12 Years Compared with Their Matched Controls

Parameter	Diabetic patients (mean ± SEM) (n = 19)	Control subjects (mean ± SEM) (n = 50)	Percentage change (%)	p value
Age (years)	51.53 ± 3.24	45.58 ± 1.74	-13.05	NS ^a
Height (cm)	167.94 ± 1.14	169.30 ± 1.08	+0.80	NS
Weight (kg)	80.05 ± 2.73	84.30 ± 1.76	+5.04	NS
FVC (liters)	3.11 ± 0.20	3.74 ± 0.66	+16.84	0.002
FEV ₁ (liters)	2.53 ± 0.18	3.13 ± 0.07	+19.16	0.0001
FEV ₁ /FVC%	81.75 ± 2.99	84.25 ± 0.83	+2.96	NS
FEF _{25–75%} (liters/s)	2.75 ± 0.27	3.76 ± 0.16	+26.86	0.002
FEF _{75–85%} (liters/s)	1.20 ± 0.14	1.50 ± 0.13	+20.00	NS

^aNonsignificant.

mean duration of disease in this group was 18.79 ± 0.80 years (mean ± SEM), with a range of 15–30 years.

Regression Analysis

Regression analyses were performed on pulmonary function data against duration of disease. Significant positive correlations for r values were found for FVC (r = 0.25, p < 0.04), FEV₁ (r = 0.28, p < 0.02), and FEF_{25–75%} (r = 0.32, p < 0.01); this information is shown in Figures 1–3, respectively.




Figure 1. Regression analysis for forced vital capacity against duration of disease in diabetic patients. A significant negative correlation was found, indicating that increased duration of disease decreased the FVC.




Figure 2. Regression analysis for forced expiratory volume in 1 second against duration of disease in diabetic patients. A significant negative correlation was found, indicating that increased duration of disease decreased the FEV₁.




Figure 3. Regression analysis for forced expiratory flow against duration of disease in diabetic patients. A significant negative correlation was found, indicating that increased duration of disease decreased the FEF_{25-75%}.

Discussion

Diabetes mellitus, an incurable lifelong disease, involves multiple systems with wide-ranging and devastating complications, which end up in severe disability and death.² Despite effective interventions directed at the complications of diabetes mellitus, including coronary artery disease, diabetic nephropathy, retinopathy, and neuropathy, the pulmonary complications of diabetes mellitus have been poorly characterized. Furthermore, there have been very little data reported on whether there is an association between years of disease and pulmonary function, and there are very few reports of pulmonary function in patients with diabetes that control for such demographic factors as age, height, weight, smoking, ethnicity, and socioeconomic status. Therefore, the present study was designed to determine the effect of diabetes in a specific Saudi ethnic group of diabetic patients by considering potential factors such as age, height, weight, smoking, or economic status. The present

study showed a correlation between duration of disease and decreased pulmonary function. This association is explained by age, height, weight, ethnic matching, and smoking. Patients with diabetes for more than 12 years experienced a significant reduction in FVC, FEV₁, and FEF_{25-75%} relative to controls.

McKeever and colleagues¹⁴ reported that an increase in mean HbA1c is associated with a decrease in lung function parameters FVC and FEV₁. They hypothesized that impaired glucose autoregulation is associated with impaired lung function. These investigators speculated that the decrease in pulmonary function, which is associated with chronic postprandial hyperglycemia, may be mediated by systemic inflammation, intracellular oxidative stress, or accumulation of advanced glycosylation end products, any of which could adversely influence lung function.

Asanuma *et al.*,¹⁵ Lange *et al.*,¹⁶ and Boulbou *et al.*³ reported that FVC and FEV₁ were reduced in subjects with diabetes compared to control subjects. Similarly, Cazzato *et al.*¹⁷ conducted a cross-sectional study to assess pulmonary function in children with type 1 diabetes and reported that FVC and FEV₁ were significantly lower in diabetics than in controls. Our results for FVC and FEV₁ confirm the results observed by Asanuma *et al.*,¹⁵ Lange *et al.*,¹⁶ Boulbou *et al.*,³ and Cazzato *et al.*¹⁷

However, Benbassat and co-workers⁸ showed that FVC, FEV₁, and FEF_{25-75%} were within the predicted values in both type 1 and type 2 diabetes populations. In addition, comparison by diabetes type showed nonsignificant differences in FEV₁ and FEF_{25-75%}. The most probable reason for this contradiction is that Benbassat *et al.*⁸ studied the pulmonary function within a group of patients with diabetes, but did not compare their results with the matched control group.

Our results are in partial agreement with those of Primhak *et al.*,¹⁸ Innocenti *et al.*,¹⁹ Makkar *et al.*,²⁰ and Boulbou *et al.*³ They performed spirometry on patients with type 1 diabetes and reported that these patients had reduced FVC, FEV₁, and FEF_{25-75%} compared to their matched controls. Our present study, which is reported in this article, describes 47 patients with diabetes, 23 of whom had type 1 diabetes and 24 of whom had type 2 diabetes.

Matsubara and Hara²¹ studied pulmonary function and microscopic changes in the lungs of diabetic patients as compared to those without diabetes and reported that the forced vital capacity, total lung capacity, residual

volume, and maximal expiratory flow rate were decreased significantly in the group with diabetes compared to the control group.

Rosenecker *et al.*²² reported that in patients with diabetes, FVC and FEV₁ declined significantly over the 5-year study period. Patients without diabetes did not experience a significant decline in these measurements during the study period.

In addition, Bell and colleagues²³ measured lung volumes in 28 young adult men with long-standing type 1 diabetes and compared the results with 16 age- and height-matched adult men without diabetes. Their results showed reduced values for both the forced expiratory volume at 1 second and the vital capacity for type 1 patients compared to the control subjects. Results are consistent with reduced lung volumes in type 1 patients and relate to duration of diabetes. Our results based on the duration of the disease are in agreement with those of Bell *et al.*²³

However, Maccioni and Colebatch²⁴ studied the effect of type 1 diabetes on pulmonary function in 22 nonsmokers and showed that for both subjects with diabetes and controls, mean values for VC, FEV₁, and total lung capacity were similar to predicted values. Their findings demonstrated that type 2 diabetes does not affect pulmonary function. The most probable reason for the lack of demonstrated risk in this study is that Maccioni and Colebatch²⁴ studied pulmonary function in 22 diabetic nonsmoker patients, but did not consider the age-, height-, weight-, and sex-matched control group; additionally, the number of diabetic patients was small. Therefore, our results are in contradiction with results observed by Maccioni and Colebatch.²⁴

The present study strongly suggests that diabetes mellitus adversely affects the pulmonary function, and results are in line with other previously conducted studies. Stratification of data demonstrated a correlation between the number of years of disease and the decline in lung function. It is advisable, therefore, that physicians should think about the lungs as potential targets for end-organ damage in diabetes, just as other organs may be targets. We recommend that patients with diabetes undergo periodic spirometry tests to assess their extent of impaired pulmonary function. These measures will help prevent early stages of pulmonary decompensation, which over time contributes to the morbidity and mortality of diabetes.

Acknowledgment:

This work was supported by Grant 02-438, College of Medicine Research Centre (CMRC), King Saud University, Riyadh, KSA.

References:

1. Narayan KM, Zhang P, Williams D, Engelgau M, Imperatore G, Kanaya A, Ramachandran A. How should developing countries manage diabetes? *CMAJ*. 2006 Sep 26;175(7):733.
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report on the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2003 Jan;26 Suppl 1:S5-20 <AUTHOR: Is this correct?>.
3. Boulbou MS, Gourgoulianis KI, Klisiaris VK, Tsikrikas TS, Stathakis NE, Molyvdas PA. Diabetes mellitus and lung function. *Med Princ Pract*. 2003 Apr-Jun;12(2):87-91.
4. Arnalich F, Hernanz A, López-Maderuelo D, Peña JM, Camacho J, Madero R, Vázquez JJ, Montiel C. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. *Horm Metab Res*. 2000 Oct;32(10):407-12.
5. Walter RE, Beiser A, Givelber RJ, O'Connor GT, Gottlieb DJ. The association between glycemic state and lung function: the Framingham Heart Study. *Am J Respir Crit Care Med*. 2003 Mar 15;167(6):911-6.
6. Cirillo D, Agrawal Y, Cassano P. Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey. *Am J Epidemiol*. 2002 May 1;155(9):842-8.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature*. 2001 Dec 13;414(6865):813-20.
8. Benbassat CA, Stern E, Kramer M, Lebzelter J, Blum I, Fink G. Pulmonary function in patients with diabetes mellitus. *Am J Med Sci*. 2001 Sep;322(3):127-32.
9. Meo SA, Al-Drees AM, Shah SF, Arif M, Al-Rubean K. Lung function in type 1 Saudi diabetic patients. *Saudi Med J*. 2005 Nov;26(11):1728-33.
10. Meo SA, Al-Drees AM, Arif M, Al-Rubean K. Lung function in type 2 Saudi diabetic patients. *Saudi Med J*. 2006 Mar;27(3):338-43.
11. Cotes JE. Lung function, assessment and application in medicine. 5th ed. Oxford: Blackwell; 1993. p. 492-3.
12. Glindmeyer HW, Lefante JJ, Jones RN, Rando RJ, Weill H. Cotton dust and cross shift change in FEV1 as predictors of annual change in FEV1. *Am J Respir Crit Care Med*. 1994 Mar;149(3 Pt 1):584-90.
13. American Thoracic Society. Standardization of spirometry. *Am Rev Respir Dis*. 1987;136: 1285-98.
14. McKeever TM, Weston PJ, Hubbard R, Fogarty A. Lung function and glucose metabolism: an analysis of data from the Third National Health and Nutrition Examination Survey. *Am J Epidemiol*. 2005 Mar 15;161(6):546-56.
15. Asanuma Y, Fujiya S, Ide H, Agishi Y. Characteristics of pulmonary function in patients with diabetes mellitus. *Diabetes Res Clin Pract*. 1985 Aug;1(2):95-101.
16. Lange P, Groth S, Kastrup J, Mortensen J, Appleyard M, Nyboe J, Jensen G, Schnohr P. Diabetes mellitus, plasma glucose and lung function in a cross-sectional population study. *Eur Respir J*. 1989 Jan;2(1):14-9.
17. Cazzato S, Bernardi F, Salardi S, Tassinari D, Corsini I, Ragni L, Cicognani A, Cacciari E. Lung function in children with diabetes mellitus. *Pediatr Pulmonol*. 2004 Jan;37(1):17-23.
18. Primhak RA, Whincup G, Tsanakas JN, Milner RD. Reduced vital capacity in insulin-dependent diabetes. *Diabetes*. 1987 Mar;36(3):324-6.

19. Innocenti F, Fabbri A, Anichini R, Tuci S, Pettinà G, Vannucci F, De Giorgio LA, Seghieri G. Indications of reduced pulmonary function in type 1 (insulin-dependent) diabetes mellitus. *Diabetes Res Clin Pract.* 1994 Oct;25(3):161-8.
20. Makkar P, Gandhi M, Agrawal RP, Sabir M, Kothari RP. Ventilatory pulmonary function tests in type 1 diabetes mellitus. *J Assoc Physicians India.* 2000 Oct;48(10):962-6.
21. Matsubara T, Hara F. The pulmonary function and histopathological studies of the lung in diabetes mellitus. *Nippon Ika Daigaku Zasshi.* 1991 Oct;58(5):528-36.
22. Rosenecker J, Höfler R, Steinkamp G, Eichler I, Smaczny C, Ballmann M, Posselt HG, Bargon J, von der Hardt H. Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome. *Eur J Med Res.* 2001 Aug 27;6(8):345-50.
23. Bell D, Collier A, Matthews DM, Cooksey EJ, McHardy GJ, Clarke BF. Are reduced lung volumes in IDDM due to defect in connective tissue? *Diabetes.* 1988 Jun;37(6):829-31.
24. Maccioni FJ, Colebatch HJ. Lung volume and distensibility in insulin-dependent diabetes mellitus. *Am Rev Respir Dis.* 1991 Jun;143(6):1253-6.